Quest Diagnostics (NYSE:DGX) Updates FY 2025 Earnings Guidance

Quest Diagnostics (NYSE:DGX - Get Free Report) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided EPS guidance of 9.630-9.830 for the period, compared to the consensus EPS estimate of 9.696. The company issued revenue guidance of $10.8 billion-$10.9 billion, compared to the consensus revenue estimate of $10.8 billion.

Quest Diagnostics Price Performance

Quest Diagnostics stock traded up $2.05 during trading hours on Thursday, hitting $172.53. 1,275,097 shares of the stock were exchanged, compared to its average volume of 1,193,311. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.31 and a current ratio of 1.09. The stock has a market capitalization of $19.26 billion, a P/E ratio of 20.66, a P/E/G ratio of 2.49 and a beta of 0.49. Quest Diagnostics has a 12 month low of $140.71 and a 12 month high of $182.38. The business's 50-day moving average is $174.79 and its two-hundred day moving average is $169.38.

Quest Diagnostics (NYSE:DGX - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.62 earnings per share for the quarter, topping the consensus estimate of $2.57 by $0.05. The firm had revenue of $2.76 billion for the quarter, compared to analysts' expectations of $2.73 billion. Quest Diagnostics had a net margin of 9.01% and a return on equity of 15.24%. The company's quarterly revenue was up 15.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.35 earnings per share. Equities research analysts expect that Quest Diagnostics will post 9.7 EPS for the current fiscal year.

Quest Diagnostics Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, July 21st. Shareholders of record on Monday, July 7th were paid a dividend of $0.80 per share. The ex-dividend date was Monday, July 7th. This represents a $3.20 annualized dividend and a yield of 1.85%. Quest Diagnostics's dividend payout ratio is 40.46%.

Wall Street Analysts Forecast Growth

DGX has been the topic of several research analyst reports. William Blair reaffirmed an "outperform" rating on shares of Quest Diagnostics in a research note on Wednesday. UBS Group decreased their price target on shares of Quest Diagnostics from $176.00 to $175.00 and set a "neutral" rating on the stock in a research note on Friday, July 18th. Evercore ISI increased their price target on shares of Quest Diagnostics from $175.00 to $180.00 and gave the company an "in-line" rating in a research note on Wednesday, April 23rd. JPMorgan Chase & Co. increased their price target on shares of Quest Diagnostics from $180.00 to $190.00 and gave the company a "neutral" rating in a research note on Tuesday, May 6th. Finally, Truist Financial increased their price target on shares of Quest Diagnostics from $190.00 to $192.00 and gave the company a "hold" rating in a research note on Wednesday. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $185.69.

Insider Transactions at Quest Diagnostics

In other Quest Diagnostics news, SVP Mark E. Delaney sold 874 shares of the firm's stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $175.72, for a total value of $153,579.28. Following the transaction, the senior vice president directly owned 8,372 shares of the company's stock, valued at approximately $1,471,127.84. This trade represents a 9.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 8.16% of the company's stock.

Hedge Funds Weigh In On Quest Diagnostics

A hedge fund recently bought a new stake in Quest Diagnostics stock. Brighton Jones LLC purchased a new position in shares of Quest Diagnostics Incorporated (NYSE:DGX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 2,144 shares of the medical research company's stock, valued at approximately $323,000. 88.06% of the stock is owned by institutional investors.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.